AEM vs RETO

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

RETO exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9, which barely places it in the 'stable' category despite catastrophic operational metrics. The company is facing a liquidity crisis with a current ratio of 0.59 and an operating margin of -133.01%, indicating it is spending far more to operate than it generates in revenue. While revenue growth is positive at 36.60%, the massive 93.4% decline in share price over the last year and a Price-to-Book ratio of 0.05 suggest the market has almost entirely written off the company's asset value. Recent short-term price gains appear to be speculative volatility rather than a fundamental recovery.